Lorena Levante
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lorena Levante has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Barbara Vischioni
Radiation Oncology Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy
1 shared publication - Cristina Fichera
Radiology Unit, Clinical Department, (CNAO) National Center for Oncological Hadrontherapy, 27100 Pavia, Italy
1 shared publication - Ester Orlandi
Department of Clinical, Surgical, Diagnostic, and Pediatric Sciences, University of Pavia, 27100 Pavia, Italy
1 shared publication - Giulia Fontana
Clinical Department, CNAO National Center for Oncological Hadrontherapy, Pavia, Italy
1 shared publication - Luca Trombetta
Medical Physics Unit, Clinical Department, (CNAO) National Center for Oncological Hadrontherapy, 27100 Pavia, Italy
1 shared publication - Maria Bonora
Radiation Oncology Unit, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy
1 shared publication
Latest Publications
- Open Access
- 28 February 2026
- Published by MDPI AG in Technologies
- Vol. 14 (3) , 144
Investigating the Radiomic Performance Gap Driven by Delineation Strategy: Radiotherapy Gross Tumor Volume vs. Dedicated Lesion Segmentation in Proton-Treated Adenoid Cystic Carcinoma
This study investigates whether dedicated tumor segmentation for radiomics (TRAD) offers any advantage over gross tumor volume (GTV) in CT radiomics for predicting adenoid cystic carcinoma (ACC) progression after proton therapy (PT). Fifty-six patients with histologically proven salivary gland ACC were included, and 107 original features were extracted using PyRadiomics v3.1.0. Signatures were selected (n = 3) with sequential backward elimination using multiple classifiers, all optimized for improving cross-validated area under the ROC curve (AUC). Signature similarity was quantified using the Spearman correlation coefficient. Random forest (RF) yielded the best discriminative performance, with no statistical difference in AUCs between contour choices (GTV: 0.87 vs. TRAD: 0.80; ΔAUCmedian = 0.0, p = 0.589). Time-to-event analysis confirmed both signatures stratified patients into distinct progression-free survival risk groups (Log-rank p < 0.0001) and demonstrated robust prognostic accuracy (GTV: C-index = 0.74, HR = 11.63; TRAD: C-index = 0.72, HR = 7.01). Biologically, GTV and TRAD signatures were borderline associated with perineural spread (p = 0.056) and solid tumor patterns (p = 0.053), respectively. Overall, CT-based radiomics models performed comparably across both segmentation strategies, supporting GTV as a practical and efficient alternative to TRAD for predicting ACC progression after PT.
- 28 February 2026
- Published by MDPI AG in Technologies
- Vol. 14 (3) , 144
Open AccessInvestigating the Radiomic Performance Gap Driven by Delineation Strategy: Radiotherapy Gross Tumor Volume vs. Dedicated Lesion Segmentation in Proton-Treated Adenoid Cystic Carcinoma
This study investigates whether dedicated tumor segmentation for radiomics (TRAD) offers any advantage over gross tumor volume (GTV) in CT radiomics for predicting adenoid cystic carcinoma (ACC) progression after proton therapy (PT). Fifty-six patients with histologically proven salivary gland ACC were included, and 107 original features were extracted using PyRadiomics v3.1.0. Signatures were selected (n = 3) with sequential backward elimination using multiple classifiers, all optimized for improving cross-validated area under the ROC curve (AUC). Signature similarity was quantified using the Spearman correlation coefficient. Random forest (RF) yielded the best discriminative performance, with no statistical difference in AUCs between contour choices (GTV: 0.87 vs. TRAD: 0.80; ΔAUCmedian = 0.0, p = 0.589). Time-to-event analysis confirmed both signatures stratified patients into distinct progression-free survival risk groups (Log-rank p < 0.0001) and demonstrated robust prognostic accuracy (GTV: C-index = 0.74, HR = 11.63; TRAD: C-index = 0.72, HR = 7.01). Biologically, GTV and TRAD signatures were borderline associated with perineural spread (p = 0.056) and solid tumor patterns (p = 0.053), respectively. Overall, CT-based radiomics models performed comparably across both segmentation strategies, supporting GTV as a practical and efficient alternative to TRAD for predicting ACC progression after PT.